Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor

Molecular Pharmacology

Volumn 72, Issue 5, 2007, Pages 1200-1209

  Braden, Michael R ^a   Nichols, David E ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ISOPROPYL 5 METHOXYTRYPTAMINE; 1 METHYL 5 HYDROXYTRYPTAMINE; 2 ETHYL 5 METHOXY 4 METHYLPHENYLISOPROPYLAMINE; 2 METHOXY 4 METHYLPHENYLISOPROPYLAMINE; 2,5 DIMETHOXY 4 IODOPHENETHYLAMINE; 2,5 DIMETHOXY 4 METHYLAMPHETAMINE; 2,5 DIMETHOXYPHENETHYLAMINE; 2,5 DIMETHOXYPHENYLISOPROPYLAMINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 5 ETHYL 2 METHOXY 4 METHYLPHENYLISOPROPYLAMINE; 5 METHOXY N,N DIMETHYLTRYPTAMINE; 5 METHOXYTRYPTAMINE; 5 METHYLTRYPTAMINE; ERGOLINE DERIVATIVE; KETANSERIN; LYSERGIDE; N,N DIMETHYLTRYPTAMINE; PHENYLALKYLAMINE; PSILOCIN; SERINE DERIVATIVE; SEROTONIN; SEROTONIN 2 AGONIST; SEROTONIN 2 RECEPTOR; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; DRUG BINDING; DRUG POTENCY; EMBRYO; HUMAN; HUMAN CELL; HYDROLYSIS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; SCANNING ELECTRON MICROSCOPY;

AMINO ACID SEQUENCE; HUMANS; HYDROGEN BONDING; LIGANDS; MOLECULAR SEQUENCE DATA; RECEPTOR, SEROTONIN, 5-HT2A; SERINE; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 35548957905     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.039255     Document Type: Article

References (46)

1. Abekawa T, Honda M, Ito K, and Koyama T (2003) Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and alpha1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats. Psychopharmacology (Berl) 169:247-256.
2. Baker D and Sali A (2001) Protein structure prediction and structural genomics. Science 294:93-96.
3. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptor. Methods Neurosci 25:366-428.
4. Braden MR, Parrish JC, Naylor JC, and Nichols DE (2006) Molecular interaction of serotonin 5 HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol 70:1956-1964.
5. Chambers JJ, Kurrasch-Orbaugh DM, and Nichols DE (2002) Translocation of the 5-alkoxy substituent of 2,5-dialkoxyarylalkylamines to the 6-position: effects on 5-HT(2A/2C) receptor affinity. Bioorg Med Chem Lett 12:1997-1999.
6. Chambers JJ and Nichols DE (2002) A homology-based model of the human 5-HT2A receptor derived from an in silico activated G-protein coupled receptor. J Comput Aided Mol Des 16:511-520.
7. 3H]ketanserin binding to 5-hydroxytryptamine2 receptors. Mol Pharmacol 43:755-761.
8. Choudhary MS, Sachs N, Uluer A, Glennon RA, Westkaemper RB, and Roth BL (1995) Differential ergoline and ergopeptine binding to 5-hydroxytryptamine2A receptors: ergolines require an aromatic residue at position 340 for high affinity binding. Mol Pharmacol 47:450-457.
9. Crozier PS, Stevens MJ, and Woolf TB (2007) How a small change in retinal leads to G-protein activation: initial events suggested by molecular dynamics calculations. Proteins 66:559-574.
10. Fersht AR (1988) Relationships between apparent binding energies measured in site-directed mutagenesis experiments and energetics of binding and catalysis. Biochemistry 27:1577-1580.
11. Fersht AR, Leatherbarrow RJ, and Wells TN (1987) Structure-activity relationships in engineered proteins: analysis of use of binding energy by linear free energy relationships. Biochemistry 26:6030-6038.
12. Gantz I, Delvalle J, Wang LD, Tashiro T, Munzert G, Guo YJ, Konda Y, and Yamada T (1992) Molecular basis for the interaction of histamine with the histamine H2 receptor. J Biol Chem 267:20840-20843.
13. Glennon RA (1989) Stimulus properties of hallucinogenic phenalkylamines and related designer drugs: formulation of structure-activity relationships. NIDA Res Monogr 94:43-67.
14. Glennon RA (1999) Arylalkylamine drugs of abuse: an overview of drug discrimination studies. Pharmacol Biochem Behav 64:251-256.
15. Glennon RA, Titeler M, and Young R (1986) Structure-activity relationships and mechanism of action of hallucinogenic agents based on drug discrimination and radioligand binding studies. Psychopharmacol Bull 22:953-958.
16. Ho BY, Karschin A, Branchek T, Davidson N, and Lester HA (1992) The role of conserved aspartate and serine residues in ligand binding and in function of the 5-HT1A receptor: a site-directed mutation study. FEBS Lett 312:259-262.
17. Johnson MP, Audia JE, Nissen JS, and Nelson DL (1993) N(1)-substituted ergolines and tryptamines show species differences for the agonist-labeled 5-HT2 receptor. Eur J Pharmacol 239:111-118.
18. Johnson MP, Loncharich RJ, Baez M, and Nelson DL (1994) Species variations in transmembrane region v of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol 45:277-286.
19. Johnson MP, Wainscott DB, Lucaites VL, Baez M, and Nelson DL (1997) Mutations of transmembrane IV and V serines indicate that all tryptamines do not bind to the rat 5-HT2A receptor in the same manner. Brain Res Mol Brain Res 49:1-6.
20. Kao HT, Adham N, Olsen MA, Weinshank RL, Branchek TA, and Hartig PR (1992) Site-directed mutagenesis of a single residue changes the binding properties of the serotonin 5-HT2 receptor from a human to a rat pharmacology. FEBS Lett 307:324-328.
21. Kristiansen K, Kroeze WK, Willins DL, Gelber EI, Savage JE, Glennon RA, and Roth BL (2000) A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism. J Pharmacol Exp Ther 293:735-746.
22. Kurrasch-Orbaugh DM, Watts VJ, Barker EL, and Nichols DE (2003) Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J Pharmacol Exp Ther 304:229-237.
23. Leurs R, Smit MJ, Tensen CP, Ter Laak AM, and Timmerman H (1994) Site-directed mutagenesis of the histamine H1-receptor reveals a selective interaction of asparagine207 with subclasses of H1-receptor agonists. Biochem Biophys Res Commun 201:295-301.
24. Li J, Edwards PC, Burghammer M, Villa C, and Schertler GF (2004) Structure of bovine rhodopsin in a trigonal crystal form. J Mol Biol 343:1409-1438.
25. Link R, Daunt D, Barsh G, Chruscinski A, and Kobilka B (1992) Cloning of two mouse genes encoding α2-adrenergic receptor subtypes and identification of a single amino acid in the mouse α2-C10 homolog responsible for an interspecies variation in antagonist binding. Mol Pharmacol 42:16-27.
26. Mansour A, Meng F, Meador-Woodruff JH, Taylor LP, Civelli O, and Akil H (1992) Site-directed mutagenesis of the human dopamine D2 receptor. Eur J Pharmacol 227:205-214.
27. Marona-Lewicka D, Kurrasch-Orbaugh DM, Selken JR, Cumbay MG, Lisnicchia JG, and Nichols DE (2002) Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats. Psychopharmacology (Berl) 164:93-107.
28. McKenna DJ, and Towers GH (1984) Biochemistry and pharmacology of tryptamines and beta-carbolines. A minireview. J Psychoactive Drugs 16:347-358.
29. McLean TH, Chambers JJ, Parrish JC, Braden MR, Marona-Lewicka D, Kurrasch-Orbaugh D, and Nichols DE (2006a) C-(4,5,6-trimethoxyindan-1-yl) methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor. J Med Chem 49:4269-4274.
30. McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, and Nichols DE (2006b) 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. J Med Chem 49:5794-5803.
31. Nichols DE (1981) Structure-activity relationships of phenethylamine hallucinogens. J Pharm Sci 70:839-849.
32. Nichols DE (1994) Medicinal chemistry and structure-activity relationships, in Amphetamine and Its Analogs (Cho AK and Segal DS eds) pp 3-41, Academic Press, New York.
33. Nichols DE (1997) Role of serotoninergic neurons and 5-HT receptors in the action of hallucinogens, in Serotoninergic Neurons and 5-HT Receptors in the CNS (Baumgarten HG and Gothert M eds) pp 563-585, Springer-Verlag, Berlin Heidelberg
34. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131-181.
35. Nichols DE and Glennon RA (1984) Medicinal chemistry and structure-activity relationships of hallucinogens, in Hallucinogens: Neurochemical, Behavioral, and Clinical Perspectives (Jacobs BL ed) pp 95-142, Raven Press, New York
36. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le T, I, Teller DC, Okada T, et al. (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289:739-745.
37. Parrish JC, Braden MR, Gundy E, and Nichols DE (2005) Differential phospholipase C activation by phenylalkylamine serotonin 5-HT 2A receptor agonists. J Neurochem 95:1575-1584.
38. Pollock NJ, Manelli AM, Hutchins CW, Steffey ME, MacKenzie RG, and Frail DE (1992) Serine mutations in transmembrane V of the dopamine D1 receptor affect ligand interactions and receptor activation. J Biol Chem 267:17780-17786.
39. Roth BL, Shoham M, Choudhary MS, and Khan N (1997) Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2a receptors. Mol Pharmacol 52:259-266.
40. Roth BL, Willins DL, Kristiansen K, and Kroeze WK (1998) 5-hydroxytryptamine2-family receptors (5-hydroxytryptamine2a, 5-hydroxytryptamine2b, 5-hydroxytryptamine2c): where structure meets function. Pharmacol Ther 79:231-257.
41. Shapiro DA, Kristiansen K, Kroeze WK, and Roth BL (2000) Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol Pharmacol 58:877-886.
42. Shulgin A and Shulgin A (1991) PIHKAL: A Chemical Love Story. Transform Press, Berkeley, CA.
43. Strader CD, Candelore MR, Hill WS, Sigal IS, and Dixon RA (1989) Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. J Biol Chem 264:13572-13578.
44. van Rhee AM and Jacobsen KA (1996) Molecular architecture of G protein-coupled receptors. Drug Dev Res 37:1-38.
45. Wang CD, Buck MA, and Fraser CM (1991) Site-directed mutagenesis of α2A-adrenergic receptors: identification of amino acids involved in ligand binding and receptor activation by agonists. Mol Pharmacol 40:168-179.
46. Wess J, Maggio R, Palmer JR, and Vogel Z (1992) Role of conserved threonine and tyrosine residues in acetylcholine binding and muscarinic receptor activation. A study with M3 muscarinic receptor point mutants. J Biol Chem 267:19313-19319.